# Pool Global Partners
High-Level Overview
Pool Global Partners is a venture capital firm founded in 2016 and headquartered in Toronto, with an additional office in San Francisco[4]. The firm positions itself as an emerging manager connecting global growth capital with deep technology, operating as an outcome-focused fund that leverages its team's expertise to identify and support high-potential tech companies[2]. The firm's investment strategy centers on early-stage companies, with a particular focus on the biotechnology and healthcare sectors, though it maintains exposure to analytics, software, and mobile technologies[1]. Pool Global Partners has demonstrated selective investment activity, typically deploying capital in rounds ranging from $1-5 million and maintaining involvement in less than two investment rounds annually[1].
The firm's impact on the startup ecosystem, while modest in scale, reflects a targeted approach to supporting deep technology ventures in North America. By concentrating on companies aged 2-3 years and working alongside established co-investors like Real Ventures, TELUS Ventures, and Radical Ventures, Pool Global Partners functions as a strategic capital provider rather than a dominant market force[1].
Origin Story
Pool Global Partners was established in 2016 by Sally Daub, who serves as the firm's Founder and Managing Partner[3]. The firm emerged during a period of growing interest in deep technology investments, positioning itself to connect global capital sources with innovative technology companies. The Toronto-based foundation reflects a deliberate choice to anchor operations in Canada's growing tech ecosystem, while the subsequent establishment of a San Francisco office signals ambitions to tap into Silicon Valley's broader network and deal flow[4].
The firm's peak activity occurred in 2017, the year following its launch, suggesting strong initial momentum in deploying its inaugural fund, which closed in January 2017[1][4]. This early focus period established the foundation for the firm's investment thesis and portfolio construction.
Core Differentiators
Investment Focus and Selectivity
Pool Global Partners distinguishes itself through a concentrated investment approach, making approximately 1-2 investments annually rather than pursuing a high-volume strategy[1]. This selectivity allows for deeper engagement with portfolio companies and more thoughtful capital deployment.
Sector Expertise in Deep Technology
The firm's portfolio reveals a pronounced emphasis on biotechnology and healthcare innovation, with six healthcare investments, three biotechnology investments, and two medical device investments among its eleven total deals[1]. This specialization in capital-intensive, science-driven sectors requires specific domain expertise and network access that differentiates the firm from generalist venture investors.
Geographic Concentration and Network
With eight of eleven investments concentrated in Canada, Pool Global Partners has established itself as a meaningful player in the Canadian startup ecosystem[1]. The firm's co-investment patterns with established partners like Real Ventures and TELUS Ventures indicate strong network positioning and the ability to syndicate deals effectively.
Outcome-Focused Philosophy
The firm's self-description as "outcome-focused" suggests a commitment to measurable results and strategic value creation beyond capital provision, though this manifests primarily through careful partner selection and staged investment approaches[2].
Role in the Broader Tech Landscape
Pool Global Partners operates within the broader context of venture capital's increasing specialization in deep technology and life sciences. The firm's emphasis on biotechnology and healthcare aligns with a significant market trend: the growing recognition that breakthrough innovations in these sectors require patient capital, specialized expertise, and extended time horizons. The timing of the firm's 2016 founding coincided with increased institutional interest in life sciences venture capital, driven by advances in synthetic biology, cell therapy, and personalized medicine.
The firm's Toronto headquarters positions it to benefit from Canada's emerging strength as a life sciences hub, particularly in biotechnology. By maintaining a San Francisco presence, Pool Global Partners bridges North American innovation ecosystems, facilitating knowledge transfer and deal flow between Silicon Valley and Canadian tech centers. This geographic arbitrage—connecting undervalued Canadian innovation with global capital—represents a meaningful contribution to reducing geographic disparities in venture funding.
The firm's selective approach also reflects a broader ecosystem trend: the recognition that not all venture capital needs to be deployed at scale. By maintaining disciplined investment criteria and focusing on companies with genuine deep technology differentiation, Pool Global Partners contributes to a more thoughtful allocation of capital toward ventures with sustainable competitive advantages.
Quick Take & Future Outlook
Pool Global Partners represents a focused, specialist approach to venture capital in an era increasingly dominated by mega-funds and generalist platforms. The firm's concentration on deep technology—particularly biotechnology—positions it well for a future where breakthrough innovations in life sciences command premium valuations and attract significant institutional capital.
The firm's modest scale and selective activity pattern suggest a deliberate strategy prioritizing quality over quantity. As the biotechnology sector continues to mature and attract larger institutional investors, Pool Global Partners' early-stage focus and Canadian market expertise could prove increasingly valuable. The firm's ability to syndicate with established partners indicates strong network positioning, which will be critical as competition for promising deep-tech deals intensifies.
Looking forward, Pool Global Partners' influence will likely remain concentrated within Canadian and North American deep-tech ecosystems rather than achieving global prominence. However, within this niche, the firm's outcome-focused philosophy and sector specialization position it as a meaningful contributor to the commercialization of breakthrough technologies. The firm's future trajectory will depend on its ability to generate strong returns from its early-stage biotechnology bets—a sector where patient capital and strategic support can meaningfully accelerate company success and ultimately validate the firm's investment thesis.
